Company Insights

ACTU supplier relationships

Explore interactive graphBrowse insights index
ACTU supplier relationship map

Actuate Therapeutics (ACTU): supplier map, financing partners, and operational constraints

Actuate Therapeutics is a clinical-stage oncology-focused biopharma that builds value by advancing proprietary GSK-3β inhibitors (notably elraglusib) through clinical development and capital markets activity until product approval and commercial sales become possible. The company currently monetizes through equity offerings and strategic financings while relying on licensed academic intellectual property and a small network of service providers to run trials and manage investigational product logistics.

For a quick supplier-risk briefing and relationship roster, visit https://nullexposure.com/ for deeper supplier intelligence and contract-level signals.

Why supplier relationships matter for an ACTU investment thesis

Actuate’s near-term progress and valuation trajectory are driven less by revenue and more by pipeline milestones and capital access. Operational continuity (supply of drug substance and clinical logistics) and transaction capacity (underwriters, legal counsel, and investor relations) are therefore critical value levers. The company executes product supply largely on purchase-order terms for clinical material while preserving certain framework arrangements for logistics support. That contracting posture creates an elevated execution risk profile relative to companies with long-term commercial supply agreements.

Key structural signals from company disclosures:

  • Contract mix is predominantly spot purchases with a single notable framework for clinical logistics — Actuate procures investigational product on a purchase-order basis but has a master services agreement with Pacific BioPharma Logistics for packaging and distribution (FY2018 master agreement; FY2024 disclosure).
  • Concentration of manufacturing for the drug substance in China is a critical operational dependency, while final drug product manufacturing takes place primarily in the U.S., exposing the company to geopolitical and supply-chain friction.
  • Supplier spend is material for a small-cap clinical-stage company — Actuate reported roughly $0.85–$0.89 million annually with Pacific BioPharma Logistics in 2023–2024, showing a recurring operational cash outflow tied to clinical logistics.

If you want to convert this analysis into procurement risk scoring and supplier monitoring, see the supplier intelligence platform at https://nullexposure.com/.

All named suppliers, advisors and counterparties — one-line investor summaries

This section lists every relationship cited in the results set and the concrete role the counterparty played.

Pacific BioPharma Logistics, Inc.

Actuate has a master services agreement with PBL for packaging, labeling, kitting, storage, distribution and inventory of its investigational products and incurred $886,905 in services from PBL in FY2024 (with an outstanding payable of ~$51.5k as of 12/31/2024). According to Actuate’s FY2024 10‑K, this relationship is active and material to clinical operations.

Lucid Capital Markets

Lucid acted as the sole book-running manager for a 2025 public offering, identifying Lucid as the primary underwriter used to raise capital in FY2025. This role was disclosed in a GlobeNewswire offering announcement in September 2025.

Newbridge Securities Corporation

Newbridge served as a co-manager for Actuate’s initial public offering, recorded in the company’s August 2024 press release announcing the IPO closing, signaling a syndicate-level placement role in FY2024.

Titan Partners Group (a division of American Capital Partners)

Titan Partners Group acted as sole bookrunner for the IPO and later served as a financial advisor on a subsequent offering, reflecting active engagement across Actuate’s capital markets transactions (IPO closing announcement August 2024; offering advisory disclosure September 2025).

Lowenstein Sandler LLP

Lowenstein Sandler represented the underwriter in the FY2025 offering, documenting the legal counsel used for underwriting-side transaction support in the September 2025 closing announcement.

Greenberg Traurig, LLP

Greenberg Traurig served as counsel to the company on the FY2025 financing, indicating established external corporate counsel for securities and transaction work, as disclosed in the same September 2025 press materials.

LifeSci Advisors, LLC

LifeSci Advisors is listed as the investor relations contact on multiple press releases in FY2026 (conference and clinical updates), functioning as the company’s outreach and investor communications adviser.

Russo Partners, LLC

Russo Partners appears as the media relations firm across FY2025–FY2026 press releases related to clinical program updates and corporate announcements, managing external narrative and media engagement.

Globe Newswire (distribution channel)

Globe Newswire distributed Actuate press releases announcing program starts and financing activity (for example the Jan 21, 2026 release on Phase 1/2 plans), serving as the company’s chosen news distribution platform for material announcements.

Oppenheimer

Oppenheimer hosted a healthcare conference where Actuate presented and made management available for one-on-one meetings, indicating sell-side investor access and potential banking relationships via conference engagement (conference participation notice in FY2026).

How the contractual picture translates into investor risk and upside

Actuate’s supplier and advisor relationships create a clear set of investment implications:

  • Operational concentration is a top risk: the company relies on a single China-based manufacturer for elraglusib drug substance while finishing occurs in the U.S.; this configuration is critical to trial continuity and regulatory timelines. (Company disclosure on geographic manufacturing split.)
  • Contracting posture increases execution volatility: using purchase-order supply for investigational product shortens committed capacity and raises the probability of supply delays or price volatility as volumes scale. (Company statements on lack of long-term supply agreements.)
  • Logistics relationship is structured as a framework: the PBL master services agreement provides continuity for clinical packaging/distribution and has represented nearly $0.9M of R&D spend annually, signaling a material operational partnership that is nevertheless not a manufacturing contract.
  • Capital markets relationships support near-term runway: underwriters (Lucid, Titan, Newbridge) and legal counsel (Greenberg Traurig, Lowenstein Sandler) show the company’s ability to complete public financings; investor relations and PR firms (LifeSci, Russo) amplify message flow around clinical readouts and offerings.
  • Licensing base validates the science but adds dependency: Actuate holds exclusive licenses from university labs for GSK‑3 inhibitors (UIC and Northwestern licenses), which create milestone/royalty obligations and legal controls that are material to commercialization economics.

Key investor checklist (short):

  • Confirm manufacturing contingency plans and secondary suppliers for DS (priority).
  • Model additional capital raises given zero current revenue and current analyst target vs. market cap.
  • Monitor legal/licensing milestones tied to university agreements that could trigger material payments or termination clauses.

For a tailored supplier-risk scorecard and contract-monitoring playbook for ACTU, visit https://nullexposure.com/ and request the company report.

Bottom line

Actuate’s valuation and near-term progression are driven by clinical milestones and the company’s ability to execute on a tightly coupled supply chain and capital markets strategy. The firm maintains a material logistics framework partner in PBL, relies on a concentrated manufacturing arrangement for drug substance, and uses a small set of underwriting and legal firms to access public markets. Investors should treat supply concentration and short-term contracting as primary operational risks and treat the capital markets relationships as the company’s current pathway to fund clinical development.

Explore contract-level exposures and continuous monitoring for Actuate at https://nullexposure.com/ to convert these relationship signals into actionable risk controls and investment decisions.